In a research report published Friday, Cowen analyst Phil Nadeau reiterated an Outperform rating on shares of Acorda Therapeutics Inc (NASDAQ:ACOR), while reducing the price …
Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are down nearly 5% in early trading Friday, after the drug maker announced that it will discontinue the development …
It would be an understatement to say the last few weeks have been harsh for biotech investors. However, I have used the dip …
Acorda Therapeutics (NASDAQ:ACOR) announced this morning the safety and tolerability data from its Phase 1 clinical trial of rHIgM22, a remyelinating antibody, which is …
J.P.
In a research report issued today, J.P.
In a research note released yesterday, Canaccord Genuity analyst John Newman maintained a Hold rating on Acorda Therapeutics (ACOR) and reduced his price …
